Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-maskedblind, Activity-controlled Phase II Clinical Study to Evaluateing the Efficacy and Safety of Intravitreal Injection of IBI302 in Patients With Diabetic Macular Edema（DME） Subjects

NCT06908876 is registered in ClinicalTrials.gov with Innovent Biologics Technology Limited (Shanghai R&D Center) as lead sponsor.

NCT NCT06908876
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06908876 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-maskedblind, Activity-controlled Phase II Clinical Study to Evaluateing the Efficacy and Safety of Intravitreal Injection of IBI302 in Patients With Diabetic Macular Edema（DME） Subjects
Lead sponsor
Innovent Biologics Technology Limited (Shanghai R&D Center)
Phase
Phase 2
Overall status
Active, not recruiting
Start date
April 24, 2025
Completion date
February 28, 2027
Enrollment
150 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic macular oedema